FOR IMMEDIATE RELEASE

Early Studies Show EBTATE is Well Tolerated and Effective in Treating Neuroendocrine Tumors

West Chester, PA, June 22, 2019-- Molecular Targeting Technologies, Inc. (MTTI) announced today that Professor Zhaohui Zhu et. al. of the Department of Nuclear Medicine, Peking Union Medical College Hospital (PUMC), Beijing, China will present "**Safety and Response of an Evans Blue-modified ^{177}Lu-labeled Octreotate in Treatment of Metastatic Neuroendocrine Tumors: A Pilot Prospective Study"** at the Society of Nuclear Medicine and Molecular Imaging (SNMMI) Annual Meeting in Anaheim this June*.

MTTI received an exclusive worldwide patent commercialization license from NIH for the Evans Blue technology. This patent estate covers ^{177}Lu-DOTA-EB-TATE (EBTATE) radiotherapeutic. Neuroendocrine neoplasm (NEN) treatment is among potential uses.

The talk describes results of a dose escalation study comparing MTTI's EBTATE to Lutathera®. EBTATE was designed to prolong circulation half-life and increase neuroendocrine tumor accumulation versus its predecessor. Dr. Zhu's team studied 26 patients in three groups with metastatic neuroendocrine neoplasms (NENs), comparing two dose levels of EBTATE to Lutathera® against CTC (Common Toxicity Criteria) for tolerability and ^{68}Ga-DOTA-TATE PET SUVmax for tumor response.

Qingxing Liu and Zhaohui Zhu highlighted, "One treatment cycle of EBTATE (^{177}Lu-DOTA-EB-TATE) 1.85 GBq (50 mCi) or 3.70 GBq (100 mCi) seems to be well tolerated and more effective than 3.7 GBq (100 mCi) of Lutathera®."

"Based on this early work, EBTATE could be the next, more effective, innovation in radiolabeled Octreotate for NEN. We're excited about this breakthrough and thank PUMC's colleagues for their exceptional contribution in our concerted effort to develop this robust molecule," said Chris Pak, President & CEO of MTTI.

MTTI is a privately held biotechnology company focused on the acquisition and development of novel technologies for treatment and diagnosis of human diseases. More information: www.mtarget.com.

Contact: Chris Pak, Email: cpak@mtarget.com; Tel: (610) 738-7938.

***Oral presentation by** Qingxin Liu, Zhaohui Zhu and Xiaoyuan Chen et. al.

Response evaluation Group

	Response			
	CR	PR	SD	PD
100mCi TATE	0	16.7% (1/6)	50% (3/6)	33.3% (2/6)
50mCi EBTATE	0	50% (3/6)	50% (3/6)	0
100mCi EBTATE	0	50% (7/14)	42.9% (6/14)	7.1% (1/14)

TATE: ^{177}Lu-DOTATATE (Lutathera®); EBTATE: ^{177}Lu-DOTA-EB-TATE (EBTATE) ; CR: Complete response; PR: partial response; SD: stable disease; PD: progressive disease



Partial Remission of Bone and Lymph Node Metastases After One Cycle of ^{177}Lu-DOTA-EBTATE (PRRT-peptide receptor radionuclide therapy).